Exjade (Deferasirox) - Summary

EXJADE SUMMARY

Exjade^® (deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125 mg, 250 mg, or 500 mg deferasirox.

Exjade^® (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

EXJADE NEWS HIGHLIGHTS

Published Studies Related to Exjade (Deferasirox)

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. [2008.04]

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. [2008.02]

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. [2008]

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. [2007.05]

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. [2006.12]

more>>

Clinical Trials Related to Exjade (Deferasirox)

Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers [Completed]

Cardiac T2* in Beta-Thalassemia Patients on Deferasirox Treatment [Active, not recruiting]

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload [Active, not recruiting]

Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis [Active, not recruiting]

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients [Active, not recruiting]

more>>